EcoDrugPlus

Folate Receptor Gamma

Ensembl ID : ENSFALG00000006276
Gene Symbol: LOC101815314
2 Cross references
423 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Follicle Stimulating Hormone Receptor

Ensembl ID : ENSFALG00000011021
Gene Symbol: FSHR
3 Cross references
200 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Fyn Related Src Family Tyrosine Kinase

Ensembl ID : ENSFALG00000010983
Gene Symbol: FRK
3 Cross references
217 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Galactosidase Alpha

Ensembl ID : ENSFALG00000025008
Gene Symbol: GLA
3 Cross references
197 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Galectin 1

Ensembl ID : ENSFALG00000012823
Gene Symbol: LGALS1
1 Cross references
331 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Galectin 3

Ensembl ID : ENSFALG00000025755
Gene Symbol: LGALS3
3 Cross references
219 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Gamma-Aminobutyric Acid Type A Receptor Subunit Alpha1

Ensembl ID : ENSFALG00000013536
Gene Symbol: GABRA1
2 Cross references
201 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Gamma-Aminobutyric Acid Type A Receptor Subunit Alpha2

Ensembl ID : ENSFALG00000002972
Gene Symbol: GABRA2
1 Cross references
201 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Gamma-Aminobutyric Acid Type A Receptor Subunit Alpha3

Ensembl ID : ENSFALG00000025401
Gene Symbol: GABRA3
3 Cross references
198 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Gamma-Aminobutyric Acid Type A Receptor Subunit Alpha4

Ensembl ID : ENSFALG00000002976
Gene Symbol: GABRA4
2 Cross references
200 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Gamma-Aminobutyric Acid Type A Receptor Subunit Alpha5

Ensembl ID : ENSFALG00000004030
Gene Symbol: GABRA5
4 Cross references
266 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Gamma-Aminobutyric Acid Type A Receptor Subunit Alpha6

Ensembl ID : ENSFALG00000013521
Gene Symbol: GABRA6
1 Cross references
266 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).